Generally, surrogate endpoints are expected to predict clinical benefits
Beyond our demonstration of the effects of GLP-1(2836) on IRI and a role for sAC in its biology, there is a small emerging body of evidence supporting a role for GLP-1(2836) in preventing obesity, insulin resistance, diabetes mellitus, and hepatic steatosis and gluconeogenesis in mice (11, 24, 27, 41, 42)
However if you start to feel unwell, or are worried you may not have successfully delivered your biologic medicine, contact your IBD team immediately - they will advise what to do next.
(2023) 108:e95662
Take a look at our advocacy Toolkit for talking points and advice on contacting policymakers about supporting coverage for weight loss medications
However, broader guidance from NICE and NHS sources offers relevant principles